A 104-week, Randomized, Open-labeled, Active-control Study on Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

Trial Profile

A 104-week, Randomized, Open-labeled, Active-control Study on Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin
  • Indications Cognition disorders; Vascular dementia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2013 New source identified and integrated: ClinicalTrials.gov record NCT01872858 (Huashan Hospital).
    • 10 Jun 2013 New source identified and integrated: ClinicalTrials.gov record NCT01872858 (Huashan Hospital).
    • 10 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top